These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25112410)

  • 21. Broadening the therapeutic scope for rapamycin treatment.
    Menzies FM; Rubinsztein DC
    Autophagy; 2010 Feb; 6(2):286-7. PubMed ID: 20081360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
    Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA
    Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deregulation of autophagy in postmortem brains of Machado-Joseph disease patients.
    Sittler A; Muriel MP; Marinello M; Brice A; den Dunnen W; Alves S
    Neuropathology; 2018 Apr; 38(2):113-124. PubMed ID: 29218765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
    Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
    J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy.
    Liu CS; Hsu HM; Cheng WL; Hsieh M
    Acta Neurol Scand; 2005 Jun; 111(6):385-90. PubMed ID: 15876340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado-Joseph disease.
    Vasconcelos-Ferreira A; Carmo-Silva S; Codêsso JM; Silva P; Martinez ARM; França MC; Nóbrega C; Pereira de Almeida L
    Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12763. PubMed ID: 34432315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
    McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
    Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward understanding Machado-Joseph disease.
    Costa Mdo C; Paulson HL
    Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
    Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
    J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment.
    Onofre I; Mendonça N; Lopes S; Nobre R; de Melo JB; Carreira IM; Januário C; Gonçalves AF; de Almeida LP
    Sci Rep; 2016 Jun; 6():28220. PubMed ID: 27328712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
    Koch P; Breuer P; Peitz M; Jungverdorben J; Kesavan J; Poppe D; Doerr J; Ladewig J; Mertens J; Tüting T; Hoffmann P; Klockgether T; Evert BO; Wüllner U; Brüstle O
    Nature; 2011 Nov; 480(7378):543-6. PubMed ID: 22113611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caloric restriction blocks neuropathology and motor deficits in Machado-Joseph disease mouse models through SIRT1 pathway.
    Cunha-Santos J; Duarte-Neves J; Carmona V; Guarente L; Pereira de Almeida L; Cavadas C
    Nat Commun; 2016 May; 7():11445. PubMed ID: 27165717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
    Ashraf NS; Duarte-Silva S; Shaw ED; Maciel P; Paulson HL; Teixeira-Castro A; Costa MDC
    Mol Neurobiol; 2019 May; 56(5):3690-3701. PubMed ID: 30187384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
    Hsieh M; Hsieh BY; Ma CY; Li YT; Liu CS; Lo CM
    J Neurosci Res; 2019 Oct; 97(10):1278-1297. PubMed ID: 31157458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease.
    Esteves S; Oliveira S; Duarte-Silva S; Cunha-Garcia D; Teixeira-Castro A; Maciel P
    Mol Neurobiol; 2019 May; 56(5):3626-3637. PubMed ID: 30173407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
    Jia D; Jiang H; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.